EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series

Hikmettullah Batgi, Fatoş Dilan Köseoğlu, Denis Çetin, Semih Başcı, Sinem Namdaroğlu, Nur Akad Soyer

Clinical Hematology International · 28.09.2026 · 8 (3)

DOI: 10.46989/001c.171328 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Hematology International, online erschienen am 28.09.2026. Verfasst von Hikmettullah Batgi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Department of Hematology, Izmir, Turkey. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal impairment is a frequent and adverse prognostic factor in multiple myeloma (MM), with dialysis-dependent patients largely excluded from pivotal trials of B-cell maturation antigen (BCMA)-directed therapies. Elranatamab, a BCMA×CD3 bispecific antibody, has demonstrated significant efficacy in relapsed/refractory multiple myeloma (RRMM); however, data in end-stage renal disease are extremely limited. We report real-world outcomes of four dialysis-dependent RRMM patients treated with elranatamab.

Results

Patients with a median age of 67 years (range 61–80) had received a median of six prior lines of therapy (range 4–7). All were refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 therapy, and none had prior BCMA-directed treatment. Baseline glomerular filtration rate ranged from 5 to 20 mL/min, and all patients were dialysis-dependent. At data cutoff, all four patients were evaluable for response. Two patients achieved complete response (CR), one achieved very good partial response, and one achieved partial response, resulting in an overall response rate of 100%. Treatment was ongoing in all four patients. Cytokine release syndrome (CRS) occurred in one patient (grade 1) and was self-limited. No immune effector cell-associated neurotoxicity syndrome (ICANS) events were observed. One patient developed severe pneumonia requiring intensive care unit admission; treatment was temporarily interrupted and successfully resumed without step-up dosing, maintaining CR. Hematologic toxicity was limited, with grade-4 lymphopenia in one patient. No dialysis-related complications or unexpected toxicities were observed. All patients received infection prophylaxis after hemodialysis, including trimethoprim–sulfamethoxazole, valacyclovir, and levofloxacin, with intravenous immunoglobulin administered.

Conclusion

In this real-world case series of dialysis-dependent RRMM patients, elranatamab demonstrated high response rates, low incidence of CRS, absence of neurotoxicity, and manageable infectious complications. These findings support the feasibility and clinical activity of elranatamab in patients undergoing hemodialysis. Larger prospective studies are warranted to confirm these encouraging results.

Schlagwörter

Stichwörter der Autor:innen

Chronic Kidney DiseaseCytokine release syndrome (CRS)ElranatamabImmune effector cell-associted neurotoxicity syndrome (ICANS)Relapsed/Refractory Multiple Myeloma

Autor:innen und Institutionen

  • Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Department of Hematology, Izmir, Turkey.
  • Department of Hematology, Faculty of Medicine, Bakırçay University, Izmir, Turkey.
  • Department of Hematology, Ege University School of Medicine, Izmir, Turkey.

Zitieren

APA

Batgi, H., Dilan Köseoğlu, F., Çetin, D., Başcı, S., Namdaroğlu, S., & Akad Soyer, N. (2026). Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series. Clinical Hematology International, 8(3). https://doi.org/10.46989/001c.171328

Vancouver

Batgi H, Dilan Köseoğlu F, Çetin D, Başcı S, Namdaroğlu S, Akad Soyer N. Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series. Clinical Hematology International. 2026;8(3). doi:10.46989/001c.171328

BibTeX
@article{Batgi2026,
  author = {Batgi, Hikmettullah and Dilan Köseoğlu, Fatoş and Çetin, Denis and Başcı, Semih and Namdaroğlu, Sinem and Akad Soyer, Nur},
  title = {Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series},
  journal = {Clinical Hematology International},
  year = {2026},
  volume = {8},
  number = {3},
  doi = {10.46989/001c.171328}
}
Kostenlos starten →